We herein report the case of an 84-year-old man with steroid-dependent adult-onset Still's disease (AOSD) whose daily steroid dose was successfully tapered after etanercept treatment. The corticosteroids worked well initially, and the patient went into remission promptly; however, he suffered a relapse due to steroid tapering. Because treatment with cyclosporine and methotrexate was ineffective, reducing the steroid dose was difficult, and the corticosteroids induced myopathy and diabetes. However, steroid tapering was accomplished in combination with etanercept therapy, and the patient's steroid-induced side effects disappeared. Etanercept should therefore be considered as a steroid-sparing treatment option in patients with steroid-responsive, steroid-dependent AOSD.
Introduction
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder characterized by spiking fevers, evanescent skin rashes, polyarthralgia, negative autoantibodies, leukocytosis, liver dysfunction and hyperferritinemia. The clinical course of patients with AOSD may be classified as characterized by either the chronic articular disease type or systemic disease type (SD type) without chronic articular involvement. Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are used to control the fever, arthritis and systemic manifestations of this disorder. Steroid monotherapy is used to achieve satisfactory control of the disease in more than three-fourths of patients with SD-type AOSD (1) . In steroid-resistant or steroid-dependent patients, the initiation of immunosuppressant therapy is often sufficient to control the disease activity. Tumor necrosis factor (TNF) inhibitors, originally developed to treat rheumatoid arthritis (RA), have been reported to be efficacious in treating AOSD, particularly in patients who exhibit an inadequate response to corticosteroids (2, 3) . However, the efficacy of etanercept (ETN), a human recombinant soluble TNF receptor, for the treatment of AOSD remains controversial. We herein report the case of an 84-year-old man with steroid-responsive, steroiddependent SD-type AOSD refractory to methotrexate (MTX) and cyclosporine (CyA), whose daily steroid dose was effectively tapered after treatment with ETN.
Case Report
In May 2011, an 84-year-old Japanese man suffering from a fever (39.0 ) and arthralgia of the hip and knee joints was admitted to a local hospital. An autoimmune disease was suspected, as antibiotics were ineffective. The patient also reported a history of interstitial pneumonia (IP) five years earlier. Although his symptoms were relieved with the short-term administration of prednisolone (PSL; 20 mg/day), he experienced exacerbation of the disease in July 2011. His symptoms quickly disappeared following the resumption of PSL therapy (15 mg/day); however, he relapsed when the steroid dose was tapered in August. A blood examination revealed an elevated white blood cell (WBC) count of 18.2× Figure) . The steroid therapy, however, induced myopathy, and he developed glucose intolerance. The dose of PSL was subsequently decreased, which resulted in further elevation of the CRP and ferritin levels. The patient was referred to our hospital for a further evaluation and treatment in October 2011. AOSD was diagnosed in accordance with the criteria published by Yamaguchi et al. (4) . The patient fulfilled three of the four major criteria for the disorder (fever, arthralgia and leukocytosis) and two of the four minor criteria (hepatic dysfunction and negativity for rheumatoid factor and antinuclear antibodies). The introduction of CyA (100 mg/day) treatment with an increased dose of steroids improved the CRP and ferritin levels. The trough serum concentration of CyA was 131 ng/dL. Simultaneously, the administration of insulin was initiated to manage the patient's hyperglycemia resulting from steroid-induced diabetes. Because the patient's CRP level increased slightly in association with PSL tapering, MTX therapy was introduced in January 2012, albeit without any significant effects on the CRP level. Meanwhile, the development of steroid-induced myopathy, diabetes and hypogammaglobulinemia made steroid tapering imperative. In March 2012, the patient's fever and arthralgia recurred and the CRP level increased to 15.0 mg/dL. The dose of PSL was 15 mg/day at that time. We decided to introduce ETN after obtaining informed consent from the patient and his family. The dose of CyA was discontinued, and treatment with ETN (50 mg/week) was initiated following the administration of methylprednisolone (mPSL; 125 mg/ day), after which the patient's symptoms promptly resolved and the CRP and ferritin levels markedly decreased to within the normal ranges. Although the patient relapsed following the discontinuation of ETN in July 2012, the readministration of ETN again induced remission. The dose of PSL was gradually tapered to 9 mg/day without relapse. The patient's steroid-induced myopathy and hypogammaglobulinemia resolved, and he eventually required less insulin therapy. As of July 2013, he remained in remission with no complications, including infection.
Discussion
The present patient was an elderly Japanese man with steroid-responsive, steroid-dependent AOSD whose daily steroid dose was successfully tapered after ETN treatment. Despite the high effectiveness of corticosteroids in controlling the clinical manifestations of AOSD, a subset of patients require the administration of intermediate-or highdose prednisone for maintenance therapy (steroid-dependent patients) despite the concomitant use of DMARDs, such as MTX, CyA or azathioprine. MTX has been broadly accepted as a first-choice therapy for steroid-dependent or steroid-resistant AOSD. CyA is also considered to be one of the most effective drugs for treating AOSD (1). However, when these drugs are ineffective or contraindicated, patients are forced to continue larger doses of corticosteroids in order to maintain disease remission, most of whom (particularly elderly patients) suffer from steroid-induced side effects. Although an insufficient starting dose of steroids (less than 40 mg/day of prednisone) has been reported to be a risk factor for relapse (5), physicians often encounter AOSD patients in whom the dose of steroids should be minimized for various reasons in actual clinical practice, as observed in our patient. At present, a growing body of literature has documented the efficacy of biologic agents in treating AOSD refractory to conventional agents, such as corticosteroids (1); however, reports regarding the steroid-sparing ability of ETN in steroid-responsive, steroid-dependent patients with AOSD are rare.
Several previous immunological studies have shown that TNF-alpha plays a pivotal role in the pathogenesis of AOSD (6), and TNF inhibitors, which are highly effective against RA, can be expected to have potential therapeutic benefits in patients with AOSD. ETN has been proven to be effective in treating patients with moderately to severely active RA who exhibit an inadequate clinical response to DMARDs both as monotherapy and in association with MTX (7, 8) . ETN has also shown efficacy in patients with other inflammatory disorders, including AOSD. We searched for published data regarding the use of ETN in the setting of AOSD and found 28 papers describing 51 patients (2, 3, 9-34). Table details the profiles, therapies and outcomes of all patients with AOSD treated with ETN. The mean age was 35.7 years, and most patients were women (70.0%). ETN was used at a dose of 50 mg weekly in most patients. Most patients exhibited an inadequate response to corticosteroids as induction therapy; however, the efficacy of corticosteroids could not be assessed accurately in many cases due to the lack of detailed information. Whether the patient had the chronic articular disease type or SD type was also not assessed in many cases. Treatment with ETN resulted in significant clinical and serological improvements in 26 of the 51 patients, although effectiveness was variably defined. Among the elderly patients (more than 60 years of age ) , two of the four patients responded to ETN (2, 26, 28, 33) . We did not observe any correlations between the response to ETN and age or gender. Only two of the 12 patients who switched from other TNF inhibitors, such as infliximab or adalimumab, responded to ETN (3, 13, 16, 18, 19, 23, 24, 28, 29, 31, 32) , suggesting that physicians should avoid the use of ETN in patients with an inadequate response to other TNF inhibitors. Three patients requiring discontinuation of ETN due to infection have been reported (3, 12, 30) .
Many reports have demonstrated the marked efficacy of anakinra, a recombinant human interleukin-1 receptor antagonist, in AOSD patients, with the efficacy being maintained over the long term (35) . The drug, however, is not currently available in Japan. Although tocilizumab (TCZ), an anti-interleukin-6-receptor monoclonal antibody, has been used with success in Japan (31), we chose to administer ETN in the present case for the following reasons. One, we speculated that ETN would be relatively safe in our patient.
Aaltonen et al. reported that ETN may be the best choice considering the safety profiles of TNF inhibitors in RA patients (36) . Because the half-life of ETN is the shortest of several biological agents approved in Japan, ETN therapy is expected to be relatively more manageable from the viewpoint of adverse events. In addition, the risk of adverse events induced by ETN treatment is comparable between patients ! 65 years of age and younger patients (37) , indicating that it may not necessarily be appropriate to consider avoiding the use of ETN because the patient is older. On the other hand, an age ! 65 years has been suggested to be a risk factor for the development of serious infections in RA patients treated with TCZ (38) . Furthermore, all ETNspecific anti-drug antibodies (ADAs) are thought to be nonneutralizing, in contrast to other TNF inhibitors. For example, infliximab (anti-TNF-alpha chimeric monoclonal antibody)-specific, adalimumab (anti-TNF-alpha human monoclonal antibody)-specific and/or certolizumab pegol (a pegylated Fab fragment of an anti-TNF-alpha humanized monoclonal antibody)-specific ADAs are able to neutralize the agent, resulting in clinical nonresponsiveness to treatment (39) . Therefore, although the reintroduction of most TNF inhibitors after a rest period carries a higher risk of further formation of ADAs, the reintroduction of ETN is associated with a lower risk. In fact, we were able to safely continue the administration of ETN for more than one year in this case, including the reintroduction of therapy after a rest period, with a concomitant reduction in the burden on the patient due to corticosteroid dose tapering. Second, we wished to prevent reductions in the CRP level resulting from TCZ treatment, as the CRP level was the most sensitive marker of the disease activity in our patient. As CRP production is primarily induced by the cytokine interleukin (IL)-6, TCZ strongly inhibits the production of CRP, independent of the disease activity.
This case report suggests that treatment with ETN may allow for the tapering of the dose of corticosteroids in selected patients with steroid-dependent AOSD. Since the pathogenesis of AOSD is very heterogeneous with a variable clinical course, the clinical benefits of ETN in patients with AOSD are inconsistent. However, we believe that it is important to bear in mind that ETN is one treatment option for steroid-dependent AOSD and its use should be considered in elderly patients in order to reduce the dose of steroids as much as possible, particularly when immunosuppressants, such as MTX and/or CyA, are ineffective. We therefore would like to emphasize the need to pay close attention to minimizing the risk of possible subsequent infection, particularly when high-dose corticosteroids are administered together. Further investigation is required to confirm the efficacy and safety of ETN in controlled clinical trials.
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